Drug Approvals - Boreal Markets

Live

TSX24,847▲ +0.44%

S&P 5005,612▲ +0.31%

Gold$3,342▼ −0.19%

BTC$108,240▲ 1.82%

WTI$78.40▲ +1.12%

USD/CAD1.3612▼ −0.08%

Silver$33.80▲ +0.62%

Uranium$92.50▲ +2.44%

TSX24,847▲ +0.44%

S&P 5005,612▲ +0.31%

Gold$3,342▼ −0.19%

BTC$108,240▲ 1.82%

WTI$78.40▲ +1.12%

USD/CAD1.3612▼ −0.08%

Silver$33.80▲ +0.62%

Uranium$92.50▲ +2.44%

Drug Approvals

July 3, 2026

Health Canada Grants 14 Drug Authorizations in Q2 2026 A Record Quarter

From biosimilars to oncology biologics, Health Canada's second quarter approval pace signals a regulatory system catching up with a global pipeline backlog.

Read full story →

Dr. Anaya Singh

Drug Approvals

Lecanemab Approved in Canada for Early Alzheimer’s A Landmark Moment for Neuroscience Investors

Dr. Anaya Singh·July 2, 2026

Drug Approvals

Dr. Anaya Singh·July 1, 2026

Drug Approvals

FDA-Health Canada Collaboration Is Cutting Drug Review Times by 18 Months

Dr. Anaya Singh·June 30, 2026

Drug Approvals

PMPRB Reforms: Canada’s New Drug Pricing Rules and What They Mean for Biotech Returns

Dr. Anaya Singh·June 28, 2026

Drug Approvals

Five Canadian Oncology Drug Approvals to Watch in H2 2026

Dr. Anaya Singh·June 26, 2026

The Boreal Brief